TY - JOUR
T1 - Association between age at diabetes onset or diabetes duration and subsequent risk of pancreatic cancer
T2 - Results from a longitudinal cohort and mendelian randomization study
AU - Shen, Baiyong
AU - Li, Yanyun
AU - Sheng, Chang Sheng
AU - Liu, Lili
AU - Hou, Tianzhichao
AU - Xia, Nan
AU - Sun, Siming
AU - Miao, Ya
AU - Pang, Yi
AU - Gu, Kai
AU - Lu, Xiongxiong
AU - Wen, Chenlei
AU - Cheng, Yi
AU - Yang, Yulin
AU - Wang, Dan
AU - Zhu, Yijie
AU - Cheng, Minna
AU - Harris, Katie
AU - Bloomgarden, Zachary T.
AU - Tian, Jingyan
AU - Chalmers, John
AU - Shi, Yan
N1 - Funding Information:
This work was supported by the Chinese National Natural Science Foundation ( 81871906 , 81770418 , 81400346 and 81270935 ), the Foundation of National Facility for Translational Medicine (Shanghai)(TMSK-2021-506) and Three-year Action Plan of Shanghai Public Health. (GWV-7).
Publisher Copyright:
© 2022 The Authors
PY - 2023/1
Y1 - 2023/1
N2 - Background: The aim of the study is to estimate the incidence of pancreatic cancer among individuals with new-onset type 2 Diabetes (T2DM) and evaluate the relationship of pancreatic cancer risk with age at diabetes onset and diabetes duration. Methods: This longitudinal cohort study included 428,362 new-onset T2DM patients in Shanghai and Mendelian randomization (MR) in the east-Asian population were used to investigate the association. Incidence rates of pancreatic cancer in all patients and by subgroups were calculated and compared to the general population. Findings: A total of 1056 incident pancreatic cancer cases were identified during eight consecutive years of follow-up. The overall pancreatic cancer annual incidence rate was 55·28/100,000 person years in T2DM patients, higher than that in the general population, with a standardized incidence ratio (SIR) of 1·54 (95% confidence interval [CI], 1·45–1·64). The incidence of pancreatic cancer increased with age and a significantly higher incidence was observed in the older groups with T2DM. However, the relative pancreatic cancer risk was inversely related to age of T2DM onset, and a higher SIR of 5·73 (95%CI, 4·49–7·22) was observed in the 20–54 years old group. The risk of pancreatic cancer was elevated at any diabetes duration. Fasting blood glucose ≥10·0 mmol/L was associated with increased risk of pancreatic cancer. MR analysis indicated a positive association between T2DM and pancreatic cancer risk. Interpretation: Efforts toward early and close follow-up programs, especially in individuals with young-onset T2DM, and the improvement of glucose control might represent effective strategies for improving the detection and results of treatment of pancreatic cancer. Funding: Chinese National Natural Science Foundation.
AB - Background: The aim of the study is to estimate the incidence of pancreatic cancer among individuals with new-onset type 2 Diabetes (T2DM) and evaluate the relationship of pancreatic cancer risk with age at diabetes onset and diabetes duration. Methods: This longitudinal cohort study included 428,362 new-onset T2DM patients in Shanghai and Mendelian randomization (MR) in the east-Asian population were used to investigate the association. Incidence rates of pancreatic cancer in all patients and by subgroups were calculated and compared to the general population. Findings: A total of 1056 incident pancreatic cancer cases were identified during eight consecutive years of follow-up. The overall pancreatic cancer annual incidence rate was 55·28/100,000 person years in T2DM patients, higher than that in the general population, with a standardized incidence ratio (SIR) of 1·54 (95% confidence interval [CI], 1·45–1·64). The incidence of pancreatic cancer increased with age and a significantly higher incidence was observed in the older groups with T2DM. However, the relative pancreatic cancer risk was inversely related to age of T2DM onset, and a higher SIR of 5·73 (95%CI, 4·49–7·22) was observed in the 20–54 years old group. The risk of pancreatic cancer was elevated at any diabetes duration. Fasting blood glucose ≥10·0 mmol/L was associated with increased risk of pancreatic cancer. MR analysis indicated a positive association between T2DM and pancreatic cancer risk. Interpretation: Efforts toward early and close follow-up programs, especially in individuals with young-onset T2DM, and the improvement of glucose control might represent effective strategies for improving the detection and results of treatment of pancreatic cancer. Funding: Chinese National Natural Science Foundation.
KW - Diabetes duration
KW - Mendelian randomization
KW - Onset age
KW - Pancreatic cancer
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85138044462&partnerID=8YFLogxK
U2 - 10.1016/j.lanwpc.2022.100596
DO - 10.1016/j.lanwpc.2022.100596
M3 - Article
AN - SCOPUS:85138044462
SN - 2666-6065
VL - 30
JO - The Lancet Regional Health - Western Pacific
JF - The Lancet Regional Health - Western Pacific
M1 - 100596
ER -